Enoxaparin Sodium Injection Articles
No Major Changes To Be Made At Rhone-Poulenc
10 February 1997
Strong Year-End Results From R-P Rorer
3 February 1997
ESSENCE Study Finds Lovenox Beats Heparin
25 November 1996
Health Care Drives 3rd Qtr For Rhone-Poulenc
4 November 1996
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
R-PR Divulges R&D Pipeline Developments
23 September 1996
Studies Show The Effectiveness Of R-PR's Lovenox
9 September 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
Rhone-Poulenc Rorer Beats 1st-Qtr Forecasts
6 May 1996
LMWH For Home Treatment Of DVT
25 March 1996
LMWH For Home Treatment Of DVT
25 March 1996
Rhone-Poulenc Rorer's "Year Of Firsts"
5 February 1996
R-PR: Lovenox news
15 January 1996
New Trials For R-PR's LMWH In Unstable Angina
4 December 1995
Heavy R&D Costs Push R-PR Profits Down By 2.1%
30 October 1995
First-Half Profits Surge At Rhone-Poulenc
31 July 1995
FDA Approves New Indication For Lovenox
27 March 1995
Search For Growth Drivers At Rhone-Poulenc Rorer
13 February 1995
1994 Transitional For R-PR With Better Second Half
6 February 1995
Fragmin Approved In USA
9 January 1995
Rhone-Poulenc Rorer's 3rd Qtr As Expected
31 October 1994
US ANTITHROMBOSIS MARKET FORECASTS
27 June 1994
NEW HORIZONS FOR THE USE OF LMW HEPARIN
30 May 1994
DECLINING 1st QTR FOR RHONE-POULENC RORER
2 May 1994
FRAGMIN APPROVABLE, SAYS FDA
24 January 1994
RHONE-POULENC: A TRANSFORMATION
16 August 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
PENDING APPLICATIONS IN US CONTINUE TO DWINDLE
19 July 1993
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
SANOFI R-PR DEAL
31 May 1993
STRONG FIRST QUARTER FOR R-PR
26 April 1993
FIRST LOW MOLECULAR WEIGHT HEPARIN IN USA
19 April 1993
RHONE-POULENC RORER SALES $4 BILLION IN 1992
8 February 1993
THROMBOEMBOLISM PREVENTION MARKET
4 January 1993
RHONE-POULENC RORER NET INCOME UP 13.4%
2 November 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
